Blue Sky Thinking: CEOs, Analysts Offer Some Thoughts On 2022
As Omicron further destabilizes the medtech space, potentially mirroring the spring of 2020, some executives shared with Medtech Insight their views on what will hopefully be a bumper year for the sector.
You may also be interested in...
The electrophysiology company announced it will reduce its workforce and take other cost-reduction measures to reduce its annual spending by $23m-$25m. Analysts suspect the company will need to raise more money from investors in 2022 or try to be acquired by a larger company.
Medtech Insight spoke to the CEOs Blackrock Neurotech, and Pixium Vision, to find out how their devices can restore lost neurological function, and how devices that interface with the brain may shape the future of medicine.
Cala Health’s FDA-cleared Cala Trio wearable for treating essential tremor is currently being tested in Parkinson’s disease patients and is targeting a $20bn global market opportunity.